Skandinaviska Enskilda Banken AB publ Has $190,000 Position in Revance Therapeutics, Inc. (NASDAQ:RVNC)

Skandinaviska Enskilda Banken AB publ lowered its holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC) by 57.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 62,041 shares of the biopharmaceutical company’s stock after selling 84,796 shares during the quarter. Skandinaviska Enskilda Banken AB publ owned about 0.06% of Revance Therapeutics worth $190,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently bought and sold shares of RVNC. FORA Capital LLC acquired a new position in Revance Therapeutics in the third quarter worth $54,000. Dynamic Technology Lab Private Ltd acquired a new position in Revance Therapeutics in the third quarter worth $88,000. GSA Capital Partners LLP acquired a new position in Revance Therapeutics in the third quarter worth $108,000. Virtu Financial LLC acquired a new position in Revance Therapeutics in the third quarter worth $120,000. Finally, Intech Investment Management LLC acquired a new position in Revance Therapeutics in the third quarter worth $231,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Analyst Upgrades and Downgrades

RVNC has been the topic of several research reports. Barclays cut their price target on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating on the stock in a research note on Monday, December 23rd. Needham & Company LLC reaffirmed a “hold” rating on shares of Revance Therapeutics in a research note on Friday, January 17th. Mizuho cut their price target on Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a research note on Tuesday, December 10th. Finally, StockNews.com initiated coverage on Revance Therapeutics in a research note on Tuesday. They set a “hold” rating on the stock. Nine analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, Revance Therapeutics presently has an average rating of “Hold” and a consensus price target of $8.39.

Revance Therapeutics Stock Performance

NASDAQ RVNC opened at $3.65 on Wednesday. The stock has a 50-day simple moving average of $3.60 and a 200 day simple moving average of $4.29. The company has a market capitalization of $381.02 million, a PE ratio of -1.89 and a beta of 0.90. Revance Therapeutics, Inc. has a 12 month low of $2.30 and a 12 month high of $6.65.

Revance Therapeutics Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.